Sun Pharma is to announce its Q1FY08 numbers. According to CNBC-TV18 estimates, the company is expected to post growth of 34% in its first quarter net profit at Rs 218.76 crore as against Rs 176.73 crore in corresponding quarter of previous year.

Net sales is seen going up 28% to Rs 601.78 crore from Rs 511.64 crore. Operating profit is likely to go up at Rs 214.7 crore versus Rs 181.01 crore and operating margin is also seen inching up to 36 % versus 35%.

Factors to watch for

• Expect good growth in both domestic & international markets
• Growth in sales from its US subsidiary Caraco
• Growth from introduction of new products in non  - US markets
• May post high other income because of forex gain through FCCB

Outlook

• To raise upto Rs 3500 crore through GDRs, FCCB, Bonds, Debentures etc
• Reduction in R& D cost on account of demreger of R& D division
• Strong opposition of Taro acquisition by Taro investors

Sales Break up

• Domestic formulation 53%
• Export formulation 34%
• Domestic bulk drugs 4%
• Export bulk drug 10%

for more on this watch video..